Transform CV Risk in Diabetes

Type 2 Diabetes Clinical Trial

— CVRiD  

Official title:

Transform CV Risk in Diabetes

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05948969
• Other study ID #: Pro00059648
• Status: Recruiting
• Phase: N/A
• Start date: September 1, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: July 2023
• Source: American College of Cardiology
• Contact: Shilpa Patel
• Phone: 2023756354
• Email: SPatel[@]acc.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This initiative supports a real-world study of practice and physician prescribing patterns and a quality improvement initiative evaluating best practices (including clinical decision support, facilitated referral to cardiometabolic team-based care model, and general educational tools/resources) to im-prove use of guideline-directed therapeutics known to lower cardiovascular risk (CV) in patients with type 2 diabetes (T2D).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 750
• Est. completion date: December 31, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• T2D diagnosis in the medical record

• ASCVD, defined as follows:

1. Known Coronary artery disease (CAD), prior Acute coronary syndrome (ACS), or coronary artery revascularization

2. Prior TIA/ischemic stroke or known carotid or intracerebral atherosclerosis, or prior carotid revascularization

3. Prior Peripheral artery disease (PAD) including symptomatic claudication or pe-ripheral revascularization

Exclusion Criteria:

• Current participation in an interventional clinical assessment of an investigational drug/device (excluding assessments related to COVID-19)

• Currently receiving any SGLT2i or GLP-1RA

• Known allergy/hypersensitivity/intolerance/contraindication to SGLT2i or GLP-1RA

• Currently receiving comfort care or enrolled in hospice

• Life expectancy <1 year

• History of or plan for heart transplantation or ventricular assist device

• Current or planned hemodialysis

• Decompensated end stage liver disease

• History of Fournier's Gangrene

• Type 1 diabetes

• Prior history of diabetic ketoacidosis

• Pregnancy or active breastfeeding

• History of Pancreatitis or pancreatic cancer

• History of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN-2)

Related Conditions & MeSH terms

• Diabetes Mellitus
• Type 2 Diabetes

Intervention

Other:
• Decision support
This implementation strategy will include the clinician education of the previous arm and apply "audit and feedback" of prior care to inform recommendations for future care. These suggestions will encompass 5 different domains based on eligibility and potential opportunity for an SGLT2i, GLP-1RA, angiotensin converting enzyme inhibitors (ACEi)/angiotensin-receptor blockers (ARB), antiplatelet or antithrombotic therapy, and statin therapy. The incorporation of clinical decision support technology will be utilized to identify tailored opportunities for each CV risk reduction based on guideline recommendations for individual patients. Clinicians will be presented prompts with patient-specific recommendation(s) for further optimization of cardioprotective agents. These prompts will be conveyed by a Study Coordinator to responsible clinicians. The follow-up clinical prompts will be based on auditing of updated clinical parameters and medication use.
• Facilitated referral to a cardiometabolic team-based center
Each site will have access to clinicians caring for patients in structured, multidisciplinary cardiometabolic centers. Clinicians caring for patients randomized to this intervention strategy will receive a facilitated referral via the EHR together). If the clinician approves the referral, the patient will be referred to this local team-based comprehensive risk factor management clinic. All patients randomized to this group will be considered in this group whether or not a visit to the cardiometabolic center is completed.

Locations

Country	Name	City	State
United States	Multiple sites nationwide	Washington	District of Columbia

Sponsors (2)

Lead Sponsor	Collaborator
American College of Cardiology	Novo Nordisk A/S

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	New prescription of a SGLT2i and/or GLP-1RA	Proportion of treatment-naïve patients who are newly prescribed a SGLT2i and/or GLP-1RA over 9 months in the facilitated referral group (Arm C) versus usual care group (Arm A)	9 months